$9.84
1.20% today
NYSE, Feb 28, 05:16 pm CET
ISIN
US6031701013
Symbol
MLYS
Sector
Industry

Mineralys Therapeutics Stock price

$9.96
-0.04 0.40% 1M
-2.24 18.36% 6M
-2.35 19.09% YTD
-6.03 37.71% 1Y
-8.48 45.99% 3Y
-8.48 45.99% 5Y
-8.48 45.99% 10Y
NYSE, Closing price Thu, Feb 27 2025
+0.28 2.89%
ISIN
US6031701013
Symbol
MLYS
Sector
Industry

Key metrics

Market capitalization $495.70m
Enterprise Value $297.51m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.59
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-192.40m
Free Cash Flow (TTM) Free Cash Flow $-166.41m
Cash position $198.19m
EPS (TTM) EPS $-3.64
P/E forward negative
Short interest 5.47%
Show more

Is Mineralys Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Mineralys Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Mineralys Therapeutics forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Mineralys Therapeutics forecast:

Buy
100%

Financial data from Mineralys Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.04 0.04
-
-
-0.04 -0.04
-
-
- Selling and Administrative Expenses 24 24
66% 66%
-
- Research and Development Expense 169 169
140% 140%
-
-192 -192
127% 127%
-
- Depreciation and Amortization 0.04 0.04
-
-
EBIT (Operating Income) EBIT -192 -192
127% 127%
-
Net Profit -178 -178
147% 147%
-

In millions USD.

Don't miss a Thing! We will send you all news about Mineralys Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Mineralys Therapeutics Stock News

Neutral
Seeking Alpha
16 days ago
Mineralys Therapeutics, Inc. (NASDAQ:MLYS ) Q4 2024 Results Conference Call February 12, 2025 8:30 AM ET Company Participants Dan Ferry - LifeSci Advisors Jon Congleton - Chief Executive Officer Adam Levy - Chief Financial Officer David Rodman - Chief Medical Officer Conference Call Participants Michael DiFiore - Evercore ISI Rich Law - Goldman Sachs Annabel Samimy - Stifel Mohit Bansal - Wells...
Neutral
GlobeNewsWire
16 days ago
– Anticipate topline data from pivotal Advance-HTN trial in March 2025 and pivotal Phase 3 Launch-HTN trial in mid first half of 2025 –
Neutral
GlobeNewsWire
23 days ago
RADNOR, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the fourth quarter and full year ...
More Mineralys Therapeutics News

Company Profile

Mineralys Therapeutics, Inc. s a clinical-stage biopharmaceutical company engaged in developing medicines to target disease, driven by abnormally elevated aldosterone. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Head office United States
CEO Jon Congleton
Employees 51
Founded 2019
Website www.mineralystx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today